BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 21926539)

  • 21. [Standardization of clinical laboratory data in Japan by the JAMT and JCCLS].
    Hosogaya S
    Rinsho Byori; 2009 Jun; 57(6):579-83. PubMed ID: 19621792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specimen allocation in longitudinal biomarker studies: controlling subject-specific effects by design.
    Tworoger SS; Yasui Y; Chang L; Stanczyk FZ; McTiernan A
    Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1257-60. PubMed ID: 15247140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurofilament ELISA validation.
    Petzold A; Altintas A; Andreoni L; Bartos A; Berthele A; Blankenstein MA; Buee L; Castellazzi M; Cepok S; Comabella M; Constantinescu CS; Deisenhammer F; Deniz G; Erten G; Espiño M; Fainardi E; Franciotta D; Freedman MS; Giedraitis V; Gilhus NE; Giovannoni G; Glabinski A; Grieb P; Hartung HP; Hemmer B; Herukka SK; Hintzen R; Ingelsson M; Jackson S; Jacobsen S; Jafari N; Jalosinski M; Jarius S; Kapaki E; Kieseier BC; Koel-Simmelink MJ; Kornhuber J; Kuhle J; Kurzepa J; Lalive PH; Lannfelt L; Lehmensiek V; Lewczuk P; Livrea P; Marnetto F; Martino D; Menge T; Norgren N; Papuć E; Paraskevas GP; Pirttilä T; Rajda C; Rejdak K; Ricny J; Ripova D; Rosengren L; Ruggieri M; Schraen S; Shaw G; Sindic C; Siva A; Stigbrand T; Stonebridge I; Topcular B; Trojano M; Tumani H; Twaalfhoven HA; Vécsei L; Van Pesch V; Vanderstichele H; Vedeler C; Verbeek MM; Villar LM; Weissert R; Wildemann B; Yang C; Yao K; Teunissen CE
    J Immunol Methods; 2010 Jan; 352(1-2):23-31. PubMed ID: 19857497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calibration of human coagulation factor VIII concentrate Ph. Eur. BRP Batch 4 for use in potency assays.
    Raut S; Costanzo A; Daniels S; Heath A; Buchheit KH
    Pharmeur Bio Sci Notes; 2010 Oct; 2010(2):1-29. PubMed ID: 21144486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast cancer predictive factor testing: the challenges and importance of standardizing tissue handling.
    Hicks DG; Kushner L; McCarthy K
    J Natl Cancer Inst Monogr; 2011; 2011(42):43-5. PubMed ID: 21672896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimized methods for fungal alpha-amylase airborne exposure assessment in bakeries and mills.
    Sander I; Zahradnik E; Bogdanovic J; Raulf-Heimsoth M; Wouters IM; Renström A; Harris-Roberts J; Robinson E; Rodrigo MJ; Goldscheid N; Brüning T; Doekes G
    Clin Exp Allergy; 2007 Aug; 37(8):1229-38. PubMed ID: 17651154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.
    Strosberg JR; Cheema A; Weber J; Han G; Coppola D; Kvols LK
    J Clin Oncol; 2011 Aug; 29(22):3044-9. PubMed ID: 21709192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival.
    Modlin IM; Gustafsson BI; Pavel M; Svejda B; Lawrence B; Kidd M
    Neuroendocrinology; 2010; 92(3):143-57. PubMed ID: 20733279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calibration of the Ph. Eur. BRP Batch 3/Mega 2 (US/FDA) standard for human coagulation factor VIII concentrate for use in the potency assay.
    Kirschbaum N; Wood L; Lachenbruch P; Weinstein M; Daas A; Rautmann G; Spieser JM; Buchheit KH
    Pharmeuropa Spec Issue Biol; 2002 Jun; 2002(1):31-64. PubMed ID: 12448031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies.
    Valentin MA; Ma S; Zhao A; Legay F; Avrameas A
    J Pharm Biomed Anal; 2011 Jul; 55(5):869-77. PubMed ID: 21530130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measurements of chromogranin B can serve as a complement to chromogranin A.
    Stridsberg M; Eriksson B; Fellström B; Kristiansson G; Tiensuu Janson E
    Regul Pept; 2007 Mar; 139(1-3):80-3. PubMed ID: 17116339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma chromogranin a: concern on laboratory investigation.
    Wiwanitkit V
    Am J Gastroenterol; 2010 Dec; 105(12):2702; author reply 2702. PubMed ID: 21131937
    [No Abstract]   [Full Text] [Related]  

  • 33. Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time.
    Jacobsen SJ; Klee GG; Lilja H; Wright GL; Oesterling JE
    Urology; 1995 Mar; 45(3):447-53. PubMed ID: 7533456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ISLH recommended reference procedure for the enumeration of particles in urine.
    Kouri T; Gyory A; Rowan RM;
    Lab Hematol; 2003; 9(2):58-63. PubMed ID: 12828299
    [No Abstract]   [Full Text] [Related]  

  • 35. Mixture classification model based on clinical markers for breast cancer prognosis.
    Zeng T; Liu J
    Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin antibody assays.
    Wong R; Favaloro E; Pollock W; Wilson R; Hendle M; Adelstein S; Baumgart K; Homes P; Smith S; Steele R; Sturgess A; Gillis D
    Pathology; 2004 Apr; 36(2):182-92. PubMed ID: 15203756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma.
    Gajjar A; Hernan R; Kocak M; Fuller C; Lee Y; McKinnon PJ; Wallace D; Lau C; Chintagumpala M; Ashley DM; Kellie SJ; Kun L; Gilbertson RJ
    J Clin Oncol; 2004 Mar; 22(6):984-93. PubMed ID: 14970185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.
    Oberthuer A; Berthold F; Warnat P; Hero B; Kahlert Y; Spitz R; Ernestus K; König R; Haas S; Eils R; Schwab M; Brors B; Westermann F; Fischer M
    J Clin Oncol; 2006 Nov; 24(31):5070-8. PubMed ID: 17075126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical testing for neuroendocrine tumors.
    Vinik AI; Silva MP; Woltering EA; Go VL; Warner R; Caplin M
    Pancreas; 2009 Nov; 38(8):876-89. PubMed ID: 19855234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.